Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

Table 3 Multivariate logistic regression: cancer vs. TZD therapy and potential confounders including combined oral anti-diabetic treatments

	Odds ratio	P	95% CI
Any TZD therapy (N = 983)	1.59	0.04	1.03–2.44
Age	1.03	0.01	1.01–1.05
Biguanide therapy	1.37	0.14	0.90–2.10
Sulfonylurea therapy	0.70	0.09	0.45–1.05
Glycosolated hemoglobin A1C, %	0.91	0.30	0.76–1.08
Body mass index, kg/m²	0.97	0.08	0.94–1.00
Cigarette smoking	0.61	0.13	0.33–1.15
High comorbidity conditions	3.40	<0.001	2.14–5.39
Number of prescription medications	1.01	0.97	0.95–1.07
Rosiglitazone therapy (N = 983)	1.89	0.02	1.11–3.19
Age	1.03	0.05	1.01–1.05
Biguanide therapy	1.34	0.16	0.89–2.04
Sulfonylurea therapy	0.70	0.10	0.46–1.07
Glycosolated hemoglobin A1C, %	0.92	0.34	0.77–1.09
Body mass index, kg/m²	0.97	0.09	0.94–1.00
Cigarette smoking	0.61	0.13	0.33–1.15
High comorbidity conditions	3.32	<0.001	2.10–5.26
Number of prescription medications	1.00	0.92	0.95–1.06
Pioglitazone therapy (N = 983)	1.09	0.76	0.62–1.94
Age	1.03	0.01	1.01–1.05
Biguanide	1.41	0.11	0.93–2.13
Sulfonylureas	0.71	0.12	0.47–1.09
Glycosolated hemoglobin A1C, %	0.91	0.27	0.77–1.08
Body mass index, kg/m²	0.98	0.12	0.91–1.01
Cigarette smoking	0.62	0.13	0.33–1.15
High comorbidity conditions	3.36	<0.001	2.12–5.32
Number of prescription medications	1.01	0.81	0.95–1.07

ISSN: 1741-7015